Advertisement

Oxaliplatin-induced Immune Thrombocytopenia: A Case Report and Literature Review

      Oxaliplatin can cause hypersensitivity-mediated immune thrombocytopenia, placing patients at risk for spontaneous bleeding.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • André T.
        • Boni C.
        • Navarro M.
        • et al.
        Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
        J Clin Oncol. 2009; 27: 3109-3116
        • de Gramont A.
        • Figer A.
        • Seymour M.
        • et al.
        Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
        J Clin Oncol. 2000; 18: 2938-2947
        • Argyriou A.A.
        • Cavaletti G.
        • Briani C.
        • et al.
        Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer.
        Cancer. 2013; 119: 438-444
        • Diaz-Rubio E.
        • Sastre J.
        • Zaniboni A.
        • et al.
        Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study.
        Ann Oncol. 1998; 9: 105-108
        • Tournigand C.
        • Cervantes A.
        • Figer A.
        • et al.
        OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
        J Clin Oncol. 2006; 24: 394-400
        • Chibaudel B.
        • Maindrault-Goebel F.
        • Lledo G.
        • et al.
        Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
        J Clin Oncol. 2009; 27: 5727-5733
        • Mori Y.
        • Nishimura T.
        • Kitano T.
        • et al.
        Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX.
        Oncology. 2010; 79: 136-143
        • Bencardino K.
        • Mauri G.
        • Amatu A.
        • et al.
        Oxaliplatin immune-induced syndrome occurs with cumulative administration and rechallenge: single institution series and systematic review study.
        Clin Colorectal Cancer. 2016; 15: 213-221
        • Ali I.
        • Wani W.A.
        • Saleem K.
        • Haque A.
        Platinum compounds: a hope for future cancer chemotherapy.
        Anticancer Agents Med Chem. 2013; 13: 296-306
        • Giantonio B.J.
        • Catalano P.J.
        • Meropol N.J.
        • et al.
        • Eastern Cooperative Oncology Group Study E3200
        Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
        J Clin Oncol. 2007; 25: 1539-1544
        • Saltz L.B.
        • Clarke S.
        • Díaz-Rubio E.
        • et al.
        Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
        J Clin Oncol. 2008; 26: 2013-2019
        • Andre T.
        • Boni C.
        • Mounedji-Boudiaf L.
        • et al.
        • Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators
        Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
        N Engl J Med. 2004; 350: 2343-2351
        • Shao Y.-Y.
        • Hu F.-C.
        • Liang J.-T.
        • Chiu W.-T.
        • Cheng A.-L.
        • Yang C.-H.
        Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions.
        J Formos Med Assoc. 2010; 109: 362-368
        • Kim B.H.
        • Bradley T.
        • Tai J.
        • Budman D.R.
        Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review.
        Oncology. 2009; 76: 231-238
        • Ichikawa Y.
        • Goto A.
        • Hirokawa S.
        • et al.
        Allergic reactions to oxaliplatin in a single institute in Japan.
        Jpn J Clin Oncol. 2009; 39: 616-620
        • Siu S.W.K.
        • Chan R.T.T.
        • Au G.K.H.
        Hypersensitivity reactions to oxaliplatin: experience in a single institute.
        Ann Oncol. 2006; 17: 259-261
        • Seki K.
        • Senzaki K.
        • Tsuduki Y.
        • et al.
        Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer.
        Int J Med Sci. 2011; 8: 210-215
        • Gowda A.
        • Goel R.
        • Berdzik J.
        • Leichman C.G.
        • Javle M.
        Hypersensitivity reactions to oxaliplatin: incidence and management.
        Oncology (Williston Park). 2004; 18 (discussion 1676, 1680, 1683-4): 1671-1675
        • Shibata Y.
        • Ariyama H.
        • Baba E.
        • et al.
        Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan.
        Int J Clin Oncol. 2009; 14: 397-401
        • Maindrault-Goebel F.
        • Andre T.
        • Tournigand C.
        • et al.
        Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients.
        Eur J Cancer. 2005; 41: 2262-2267
        • Jardim D.L.
        • Rodrigues C.A.
        • Novis Y.A.S.
        • Rocha V.G.
        • Hoff P.M.
        Oxaliplatin-related thrombocytopenia.
        Ann Oncol. 2012; 23: 1937-1942
        • Overman M.J.
        • Maru D.M.
        • Charnsangavej C.
        • et al.
        Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury.
        J Clin Oncol. 2010; 28: 2549-2555
        • Slade J.H.
        • Alattar M.L.
        • Fogelman D.R.
        • et al.
        Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury.
        Clin Colorectal Cancer. 2009; 8: 225-230
        • Taleghani B.M.
        • Meyer O.
        • Fontana S.
        • et al.
        Oxaliplatin-induced immune pancytopenia.
        Transfusion. 2005; 45: 704-708
        • Curtis B.R.
        • Kaliszewski J.
        • Marques M.B.
        • et al.
        Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin.
        Am J Hematol. 2006; 81: 193-198
        • Bautista M.A.
        • Stevens W.T.
        • Chen C.-S.
        • Curtis B.R.
        • Aster R.H.
        • Hsueh C.-T.
        Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature.
        J Hematol Oncol. 2010; 3: 12
        • Forcello N.P.
        • Khubchandani S.
        • Patel S.J.
        • Brahaj D.
        Oxaliplatin-induced immune-mediated cytopenias: a case report and literature review.
        J Oncol Pharm Pract. 2015; 21: 148-156
        • Ito I.
        • Ito Y.
        • Mizuno M.
        • et al.
        A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin.
        Clin Exp Nephrol. 2012; 16: 490-494
        • Saif M.W.
        • The A.
        • Ledbetter L.
        Oxaliplatin-mediated autoimmune thrombocytopenia.
        Clin Colorectal Cancer. 2009; 8: 61-62
        • Griffiths R.
        • Mikhael J.
        • Gleeson M.
        • Danese M.
        • Dreyling M.
        Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma.
        Blood. 2011; 118: 4808-4816
        • Beg M.S.
        • Komrokji R.S.
        • Ahmed K.
        • Safa M.M.
        Oxaliplatin-induced immune mediated thrombocytopenia.
        Cancer Chemother Pharmacol. 2008; 62: 925-927
        • Curtis B.R.
        • Hsu Y.-M.S.
        • Podoltsev N.
        • et al.
        Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies.
        Blood. 2018; 131: 1486-1489
        • Fontão-Wendel R.
        • Hoff P.M.
        • Lazar A.
        • et al.
        Immune-mediated pancytopenia induced by oxaliplatin: a case report.
        Transfusion. 2010; 50: 1453-1459
        • Garciaz S.
        • Oziel-Taieb S.
        • Dermeche S.
        • Ries P.
        • Vessaud J.
        • Raoul J.-L.
        Acute immune hematological complication of oxaliplatin. A series of 3 cases.
        Tumori. 2014; 100: e17-e19
        • van den Bemt P.M.L.A.
        • Meyboom R.H.B.
        • Egberts A.C.G.
        Drug-induced immune thrombocytopenia.
        Drug Saf. 2004; 27: 1243-1252
        • George J.N.
        • Raskob G.E.
        • Shah S.R.
        • et al.
        Drug-induced thrombocytopenia: a systematic review of published case reports.
        Ann Intern Med. 1998; 129: 886-890
        • Arnold D.M.
        • Kukaswadia S.
        • Nazi I.
        • et al.
        A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia.
        J Thromb Haemost. 2013; 11: 169-176
        • Aster R.H.
        • Curtis B.R.
        • McFarland J.G.
        • Bougie D.W.
        Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management.
        J Thromb Haemost. 2009; 7: 911-918
        • Aster R.H.
        Can drugs cause autoimmune thrombocytopenic purpura?.
        Semin Hematol. 2000; 37: 229-238
        • Graham M.A.
        • Lockwood G.F.
        • Greenslade D.
        • Brienza S.
        • Bayssas M.
        • Gamelin E.
        Clinical pharmacokinetics of oxaliplatin: a critical review.
        Clin Cancer Res. 2000; 6: 1205-1218
        • George J.N.
        • Aster R.H.
        Drug-induced thrombocytopenia: pathogenesis, evaluation, and management.
        Hematol Am Soc Hematol Educ Progr. 2009; : 153-158